ArticleEuropean journal of heart failure2024

A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial.

Dalane W Kitzman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.